Main Article Content

Jak Ozsarfati
Gideon Koren


Medications, Disruptive Behavior


The majority of children with FASD suffer from disruptive behaviors and most of them need medications to modify these behaviors. The objective of this review is to familiarize professionals caring for children with FASD with stimulants and other drugs for ADHD, and the second generation antipsychotic risperidone - for aggressive and defiant behaviors.

Abstract 764 | PDF Downloads 682


1. The American Academy of Pediatrics. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/ hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007– 22.
2. The American Psychiatric Association. Task force on DSM -IV. Diagnostic and statistical manual of mental disorders: DSM -IV-TR. 4th ed. Washington, DC: American Psychiatric Association, 2010.
3. Clavenna A, Bonati M. Safety of medicines used for ADHD in children: a review of published prospective clinical trials. Arch Dis Child 2014;99:866– 872.
4. The American Academy of Pediatrics/American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr 2008 Aug;29(4):335.
5. Martinez -Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention -deficit hyperactivity disorder. CNS Drugs 2013 Jan;27(1):15- 30.
6. Doig J, McLennan JD, Gibbard WB. Medication effects on symptoms of attention-deficit/hyperactivity disorder in children with fetal alcohol spectrum disorder. J Child Adolesc Psychopharmacol 2008;18(4):365– 371.
7. Childress A, Sallee FR. The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD. Expert Rev Neurother 2013 Sep;13(9):979- 88.
8. Lexicomp Online ®, Pediatric & Neonatal Lexi - Drugs ®, Hudson, Ohio: Lexi -Comp, Inc.; February 05, 2015.
9. Ghuman JK, Arnold LE, Anthony BJ. Psychopharmacological and other treatments in preschool children with attention-deficit/ hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol 2008; 18(5):413- 47.
10. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45(11):1284- 93.
11. Dopheide JA, Pliszka SR. Attention -deficit - hyperactivity disorder: an update. Pharmacotherapy 2009; 29(6):656- 79.
12. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(7):894- 921.
13. Arnold LE, Lindsay RL, López FA, et al. Treating attention-deficit/ hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007; 120(5):1100- 6.
14. Swanson JM, Hinshaw SP, Arnold LE, Gibbons RD, Marcus S, Hur K, Jensen PS, Vitiello B, Abikoff HB, Greenhill LL, Hechtman L, Pelham WE, Wells KC, Conners CK, March JS, Elliott GR, Epstein JN, Hoagwood K, Hoza B, Molina BS, Newcorn JH, Severe JB, Wigal T. Secondary evaluations of MTA 36 -month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 2007 Aug;46(8):1003- 14.
15. Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol 2006 Aug;16(4):379- 92.
16. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004 Nov;114(5):e634- 41.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>